Mountzios G - Search Results

1

Aurora kinases as targets for cancer therapy.

Mountzios G, Terpos E, Dimopoulos MA. Mountzios G, et al. Cancer Treat Rev. 2008 Apr;34(2):175-82. doi: 10.1016/j.ctrv.2007.09.005. Epub 2007 Nov 19. Cancer Treat Rev. 2008. PMID: 18023292 Review.

2

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.

Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans AM, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, West H, Besse B. Mountzios G, et al. Ann Oncol. 2019 Nov 1;30(11):1686-1688. doi: 10.1093/annonc/mdz295. Ann Oncol. 2019. PMID: 31504132 Free article. No abstract available.

3

Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature.

Pavlakis G, Mountzios G, Terpos E, Leivaditou A, Papadopoulos G, Papasavas P. Pavlakis G, et al. Among authors: mountzios g. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:299-303. doi: 10.1111/j.1525-1438.2006.00208.x. Int J Gynecol Cancer. 2006. PMID: 16515608 Review.

4

Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.

Mountzios G, Bamias A, Voulgaris Z, Rodolakis A, Vlahos G, Gourgoulis G, Papaiakovou EE, Giannopoulos A. Mountzios G, et al. Gynecol Oncol. 2008 Jan;108(1):130-5. doi: 10.1016/j.ygyno.2007.08.093. Epub 2007 Nov 7. Gynecol Oncol. 2008. PMID: 17988722

5

Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data.

Mountzios G, Dimopoulos MA, Soria JC, Sanoudou D, Papadimitriou CA. Mountzios G, et al. Crit Rev Oncol Hematol. 2010 Aug;75(2):94-109. doi: 10.1016/j.critrevonc.2009.10.002. Epub 2009 Nov 13. Crit Rev Oncol Hematol. 2010. PMID: 19914087 Review.

6

Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies.

Mountzios G, Sanoudou D, Syrigos KN. Mountzios G, et al. Curr Pharm Des. 2010;16(20):2184-93. doi: 10.2174/138161210791792859. Curr Pharm Des. 2010. PMID: 20459386

7

All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer.

Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, Bafaloukos D, Kosmidis P, Murray S. Linardou H, et al. Among authors: mountzios g. Cancer Treat Rev. 2011 May;37(3):221-33. doi: 10.1016/j.ctrv.2010.07.008. Epub 2010 Sep 29. Cancer Treat Rev. 2011. PMID: 20817364 Review.

8

Developments in the systemic treatment of endometrial cancer.

Mountzios G, Pectasides D, Bournakis E, Pectasides E, Bozas G, Dimopoulos MA, Papadimitriou CA. Mountzios G, et al. Crit Rev Oncol Hematol. 2011 Sep;79(3):278-92. doi: 10.1016/j.critrevonc.2010.07.013. Epub 2010 Sep 15. Crit Rev Oncol Hematol. 2011. PMID: 20833559 Review.

9

A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.

Mountzios G, Syrigos KN. Mountzios G, et al. Drug Saf. 2011 Mar 1;34(3):175-86. doi: 10.2165/11586540-000000000-00000. Drug Saf. 2011. PMID: 21332242 Review.

10

Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.

Mountzios G, Ramfidis V, Terpos E, Syrigos KN. Mountzios G, et al. Clin Lung Cancer. 2011 Nov;12(6):341-9. doi: 10.1016/j.cllc.2011.03.032. Epub 2011 May 17. Clin Lung Cancer. 2011. PMID: 21703936 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results